Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER3 monoclonal antibody SIBP-03

A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 3 (HER3; ERBB3), with potential antineoplastic activity. Upon administration, anti-HER3 monoclonal antibody SIBP-03 targets and binds to HER3 and inhibits its activation. This may prevent HER3-mediated signaling and inhibit HER3-dependent tumor cell proliferation and differentiation. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors and is associated with poor prognosis and drug resistance; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:SIBP 03
SIBP-03
SIBP03
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search